GPCR Therapeutics USA is a newly incorporated Biotechnology company in the Bay area originatinating from GPCR Therapeutics Inc., Korea. Our mission is to discover and develop innovative therapeutics targeting cancer based on the novel science of G protein coupled receptors (GPCR) heteromers. The most advanced clinical candidate, Burixafor, is planned to initiate a clinical trial in the US next year, focusing on our CXCR4 heteromer hypothesis. Additionally, we will be utilizing our technologies to identify key GPCR heteromers as therapeutics targets in Oncology. Dr. Pina Cardarelli will be heading up the team of talented researchers that will be expanding in the coming years.